Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.
about
Emerging drugs for chronic lymphocytic leukaemia.Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.Thalidomide-associated thrombocytopenia.Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.The use of novel agents in the treatment of relapsed and refractory multiple myelomaThalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.Cure of myeloma: hype or reality?Thalidomide: present and future in multiple myeloma.Targeted therapy in multiple myeloma.Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues.The future role of thalidomide in multiple myeloma.A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma.Pharmacotherapy of multiple myeloma.Retrospective analysis of 264 multiple myeloma patients.The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.Thalidomide in multiple myeloma: past, present and future.Current status of new drugs for the treatment of patients with multiple myeloma.An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myelomaMaintenance therapy for multiple myeloma with particular emphasis on thalidomide.Tolerance to chemotherapy in elderly patients with cancer.Current treatment options in follicular lymphoma: science and bias.Treatment of relapsed and refractory myeloma.The role of high-dose chemotherapy followed by peripheral blood stem cell transplantation for the treatment of multiple myeloma.Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.Novel immunomodulatory compounds in multiple myeloma.Second auto-SCT for treatment of relapsed multiple myeloma.Predicting durable remissions following thalidomide therapy for relapsed myeloma.The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma.Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma.Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma.First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma.Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.Overview of drug therapy for multiple myeloma.Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the International Staging System.
P2860
Q30353154-96C25F4B-535F-4CDD-9923-DA1ABA92B3A6Q33289791-BB599420-DB85-4F2D-B5FA-1E7D27A7837AQ33368888-2401B1C4-D079-4C2C-BBD6-5E7CC209A261Q33374964-21D75027-9650-491C-A0BF-4EF28C235736Q35097319-E7CB31A1-D453-49AD-A5F9-57B4D906D725Q35930659-07388E16-FDD0-4736-9FC5-1C0E718F79C9Q35949091-BACD8BB8-2910-46B2-8826-B518008DD09AQ36066131-63C283C9-53F1-4783-B2B3-3B366E8CF3D6Q36108614-1815F13D-7505-4611-B40F-2ED75B852852Q36132803-A1D31C6F-14EE-41CF-AEED-92D53E9F87F0Q36258705-6D1954C6-94D0-431D-9216-5CC49CA254DFQ36381565-C4BF05AE-3511-4E50-BB5A-CBC8E70F9868Q36429735-AD80D34C-B0F8-4423-862B-2878739707D5Q36611531-AADD8D5B-5743-4149-912B-3CB8C3A8A1DFQ36612613-8E3C3E34-9650-4E9E-B83B-DFE54F500A94Q36616493-F0A03920-F097-4B7B-83A0-7E3C7291E83CQ36649839-D7B5A880-8CD2-4BD8-ACD9-DC3F4945E2BFQ36695180-20BFF3B7-5D9D-4370-9474-F126F1FC0A8AQ36698947-7E2779DC-BBAE-4AD8-A124-C4B55D335788Q36715266-8A7812F2-16F8-47B9-8922-4FFFEC1BC096Q36966780-01939ED7-F9AE-46EB-9805-B0D5AC1035C6Q37209929-DF841D6A-8EED-4CF0-A555-7188680EB1A5Q37209935-615A4A97-019F-47E7-8388-5EEE22C8FFCAQ37831402-6FD8D713-0563-43C0-8E32-8D1D2544E1E7Q38065298-7F985421-8DCA-4D68-9D88-12241AEA5C55Q38069614-C17BCA7E-4258-4302-9E9A-0EFC77C52588Q44758991-60E8FBDD-C209-43EA-9B8A-7AFAC43019E5Q44763325-236DCF2D-34FD-473D-B570-97180108369AQ44770291-0B7AB0DD-C75F-47E6-A420-612D9C28B6AEQ45128205-D5B99C64-9D75-426F-B852-44FA7A4DE31AQ45918038-53827FE6-3493-4D72-BA6B-55F7CA0D8DCCQ46558044-B858D452-3FBF-44D1-8A62-0C28EDA375DAQ46804697-96D582C7-AEDF-4E1C-A857-147B2D4AF996Q46877525-06EA4ED0-160D-4621-B128-48F215AC639AQ53242836-D2AF0226-67E5-4E15-828E-C6164DDD1C24
P2860
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Multicenter phase 2 trial of t ...... nostic impact of advanced age.
@en
Multicenter phase 2 trial of t ...... nostic impact of advanced age.
@nl
type
label
Multicenter phase 2 trial of t ...... nostic impact of advanced age.
@en
Multicenter phase 2 trial of t ...... nostic impact of advanced age.
@nl
prefLabel
Multicenter phase 2 trial of t ...... nostic impact of advanced age.
@en
Multicenter phase 2 trial of t ...... nostic impact of advanced age.
@nl
P2093
P1433
P1476
Multicenter phase 2 trial of t ...... nostic impact of advanced age.
@en
P2093
Andrew Grigg
Craig Underhill
H Miles Prince
James J Biagi
Jennifer G Smith
Jerome B Zeldis
Joe McKendrick
John F Seymour
Kate Lillie
Linda Mileshkin
P356
10.1182/BLOOD-2002-09-2846
P407
P577
2003-03-13T00:00:00Z